Search

Your search keyword '"Chiu, C-H."' showing total 319 results
Start Over Author "Chiu, C-H." Search Limiters Full Text
319 results on '"Chiu, C-H."'

8. OA01.07 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations

Author

Bazhenova, L., primary, Chih-Hsin Yang, J., additional, Wang, M., additional, Mitchell, P., additional, Camidge, D. Ross, additional, Fang, J., additional, Nian, W., additional, Chiu, C.-H., additional, Zhou, J., additional, Zhao, Y., additional, Su, W.-C., additional, Yang, T.-Y., additional, Zhu, V.W., additional, Millward, M., additional, Fan, Y., additional, Huang, W.-T., additional, Cheng, Y., additional, Jiang, L., additional, Zheng, L., additional, and Janne, P.A., additional

Published
2023
Full Text
View/download PDF

13. 264P Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC)

Author

Lu, S., primary, Fan, Y., additional, Chiu, C-H., additional, Yu, Y., additional, Loong, H.H.F., additional, Lin, C-C., additional, Dong, X., additional, Li, J., additional, Zhao, J., additional, Zhang, Z., additional, Zhao, N., additional, Xu, T., additional, Hou, M., additional, Wang, D., additional, and Hu, X., additional

Published
2022
Full Text
View/download PDF

14. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722

Author

Mok, T.S.K., primary, Nakagawa, K., additional, Park, K., additional, Ohe, Y., additional, Girard, N., additional, Kim, H.R., additional, Wu, Y-L., additional, Gainor, J., additional, Lee, S-H., additional, Chiu, C-H., additional, Sang-We, K., additional, Cheng-Ta, Y., additional, Liang, W., additional, Wu, L., additional, Lin, M-C., additional, Samol, J., additional, Zhang, X., additional, Sylvester, J., additional, Li, S., additional, and Yang, J.C-H., additional

Published
2022
Full Text
View/download PDF

15. MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

Author

Fan, Y., primary, Drilon, A., additional, Chiu, C.-H., additional, Bowles, D.W., additional, Loong, H.H.F., additional, Siena, S., additional, Goto, K., additional, Krzakowski, M., additional, Ahn, M.-J., additional, Murakami, H., additional, Dziadziuszko, R., additional, Zeuner, H., additional, Pitcher, B., additional, Cheick, D., additional, and Krebs, M.G., additional

Published
2022
Full Text
View/download PDF

16. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment

Author

Yang, J.C.-H., primary, Wang, M., additional, Mitchell, P., additional, Fang, J., additional, Nian, W., additional, Chiu, C-h., additional, Zhou, J., additional, Zhao, Y., additional, Su, W.-C., additional, Camidge, R., additional, Yang, T.-Y., additional, Zhu, V., additional, Millward, M., additional, Fan, Y., additional, Huang, W.-T., additional, Cheng, Y., additional, Jiang, L., additional, Brungs, D., additional, Bazhenova, L.B., additional, Lee, C.K., additional, Gao, B., additional, Zheng, L., additional, and Janne, P., additional

Published
2022
Full Text
View/download PDF

20. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.

Author

Drilon, A, Chiu, C-H, Fan, Y, Cho, BC, Lu, S, Ahn, M-J, Krebs, MG, Liu, SV, John, T, Otterson, GA, Tan, DSW, Patil, T, Dziadziuszko, R, Massarelli, E, Seto, T, Doebele, RC, Pitcher, B, Kurtsikidze, N, Heinzmann, S, Siena, S, Drilon, A, Chiu, C-H, Fan, Y, Cho, BC, Lu, S, Ahn, M-J, Krebs, MG, Liu, SV, John, T, Otterson, GA, Tan, DSW, Patil, T, Dziadziuszko, R, Massarelli, E, Seto, T, Doebele, RC, Pitcher, B, Kurtsikidze, N, Heinzmann, S, and Siena, S

Abstract

INTRODUCTION: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion-positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion-positive NSCLC with the central nervous system (CNS)-only progression post-crizotinib is reported. METHODS: Adults with ROS1 fusion-positive, locally advanced or metastatic NSCLC who received at least one dose of entrectinib and had 12 months or longer of follow-up were included in the analysis. Co-primary end points were confirmed objective response rate (ORR) and duration of response (DoR) by blinded independent central review. The data cutoff was on August 31, 2020. RESULTS: The efficacy-assessable population comprised 168 ROS1 TKI-naïve patients. The median survival follow-up was 29.1 months (interquartile range, 21.8-35.9). The ORR was 68% (95% confidence interval [CI]: 60.2-74.8); the median DoR was 20.5 months. The median progression-free survival (PFS) was 15.7 months and the median OS was 47.8 months. In the 25 patients with measurable baseline CNS metastases, the intracranial ORR was 80% (95% CI: 59.3-93.2), median intracranial DoR was 12.9 months, and median intracranial PFS was 8.8 months. Among 18 patients with CNS-only progression on previous crizotinib treatment, two achieved a partial response (11%) and four had stable disease (22%). In seven patients with measurable CNS disease from this cohort, the intracranial ORR was 14% (1 partial response). CONCLUSIONS: Entrectinib is active and achieves prolonged survival in ROS1 TKI-naïve patients with ROS1 fusion-positive NSCLC. Modest activity is seen in patients with CNS-only progression post-crizotinib.

Published
2022

21. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors

Author

Demetri, GD, De Braud, F, Drilon, A, Siena, S, Patel, MR, Cho, BC, Liu, S, Ahn, M-J, Chiu, C-H, Lin, JJ, Goto, K, Lee, J, Bazhenova, L, John, T, Fakih, M, Chawla, SP, Dziadziuszko, R, Seto, T, Heinzmann, S, Pitcher, B, Chen, D, Wilson, TR, Rolfo, C, Demetri, GD, De Braud, F, Drilon, A, Siena, S, Patel, MR, Cho, BC, Liu, S, Ahn, M-J, Chiu, C-H, Lin, JJ, Goto, K, Lee, J, Bazhenova, L, John, T, Fakih, M, Chawla, SP, Dziadziuszko, R, Seto, T, Heinzmann, S, Pitcher, B, Chen, D, Wilson, TR, and Rolfo, C

Abstract

PURPOSE: Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable [median duration of response (DoR) 10.4 months] responses in adults with NTRK fusion-positive solid tumors from three phase I/II trials. This article expands prior reports with additional patients and longer follow-up. PATIENTS AND METHODS: Patients with locally advanced/metastatic NTRK fusion-positive solid tumors and ≥12 months' follow-up were included. Primary endpoints were ORR and DoR by blinded independent central review (BICR); secondary endpoints included progression-free survival (PFS), intracranial efficacy, and safety. The safety-evaluable populations included all patients who had received ≥1 entrectinib dose. RESULTS: At clinical cut-off (August 31, 2020), the efficacy-evaluable population comprised 121 adults with 14 tumor types and ≥30 histologies. Median follow-up was 25.8 months; 61.2% of patients had a complete (n = 19) or partial response (n = 55). Median DoR was 20.0 months [95% confidence interval (CI), 13.0-38.2]; median PFS was 13.8 months (95% CI, 10.1-19.9). In 11 patients with BICR-assessed measurable central nervous system (CNS) disease, intracranial ORR was 63.6% (95% CI, 30.8-89.1) and median intracranial DoR was 22.1 (95% CI, 7.4-not estimable) months. The safety profile of entrectinib in adults and pediatric patients was aligned with previous reports. Most treatment-related adverse events (TRAEs) were grade 1/2 and manageable/reversible with dose modifications. TRAE-related discontinuations occurred in 8.3% of patients. CONCLUSIONS: With additional clinical experience, entrectinib continues to demonstrate durable systemic and intracranial responses and can address the unmet need of a CNS-active treatment in patients with NTRK fusion-positive solid tumors.

Published
2022

22. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Author

Wang, M, Yang, JC-H, Mitchell, PL, Fang, J, Camidge, DR, Nian, W, Chiu, C-H, Zhou, J, Zhao, Y, Su, W-C, Yang, T-Y, Zhu, VW, Millward, M, Fan, Y, Huang, W-T, Cheng, Y, Jiang, L, Brungs, D, Bazhenova, L, Lee, CK, Gao, B, Xu, Y, Hsu, W-H, Zheng, L, Janne, PA, Wang, M, Yang, JC-H, Mitchell, PL, Fang, J, Camidge, DR, Nian, W, Chiu, C-H, Zhou, J, Zhao, Y, Su, W-C, Yang, T-Y, Zhu, VW, Millward, M, Fan, Y, Huang, W-T, Cheng, Y, Jiang, L, Brungs, D, Bazhenova, L, Lee, CK, Gao, B, Xu, Y, Hsu, W-H, Zheng, L, and Janne, PA

Abstract

UNLABELLED: Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack of effective therapy, the prognosis of these patients is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins and other mutations. In both cell lines and xenograft models, sunvozertinib shows potent antitumor activity. In the two ongoing phase I clinical studies, sunvozertinib was tolerated up to 400 mg once daily. The most common drug-related adverse events included diarrhea and skin rash. Antitumor efficacy was observed at the doses of 100 mg and above in patients with EGFRexon20ins NSCLC across different subtypes, with prior amivantamab treatment as well as with baseline brain metastasis. The median duration of response has not been reached. SIGNIFICANCE: We report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.

Published
2022

24. Directional growth effect on magneto-mechanical properties of Fe81Al19 alloy.

Author

Chang, H. W., Jen, S. U., Liao, Y. H., Wong, Y. J., Chiu, C. H., and Chang, W. C.

Subjects
ALLOYS, HEAT flux, DIRECTIONAL solidification, SINGLE crystals, MAGNETOSTRICTION, ELECTRICAL steel
Abstract

Directional growth effect on magneto-mechanical properties of Fe81Al19 alloy is studied. The ideal model of heat flux for directional solidification (DS) technique is proposed, and the tuned A/L (the ratio of cross-sectional area and length for the ingot) and ΔT (temperature difference) are adopted to increase heat flux (q). The experimental result shows that the increase of q effectively promotes the degree of (011)[100] Goss texture and therefore helps to form an oriented stripe domain structure. Large λ100 of 93.8 ppm attained for this optimized Fe81Al19 alloy prepared by DS method is very close to that of the Fe81Al19 single crystal (95.0 ppm). For the optimized DS prepared Fe81Al19 alloy, high magnetostriction sensitivity (dλ/dH) of 0.45 ppm/Oe leads to huge ΔEs/E0 of ∼10% and attractive ΔE/E0 of 8.2% at small H = 0.25 kOe. The above remarkable magneto-mechanical properties, low cost of Fe81Al19, and simple process of DS favor for applications. This work proposes an ideal model to emphasize the importance of heat flux in DS, and experimentally attains the remarkable magneto-mechanical properties for Fe81Al19 alloy prepared by DS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. High-coercivity heavy-rare-earth-free NdFeB sintered magnets developed by doping Ce85Al15 and grain boundary diffusion with Pr70Cu15Al15.

Author

Wong, Y. J., Chang, H. W., Lee, Y. I., Chang, W. C., Chiu, C. H., and Mo, C. C.

Subjects
KIRKENDALL effect, MAGNETS, MAGNETIC anisotropy, ALLOY powders, RARE earth metals
Abstract

Traditional NdFeB sintered magnets with coercivity larger than 20 kOe, called super-high (SH) level, usually contains considerable amount of high-cost heavy rare earth (HRE), such as Dy or Tb. In this work, high coercivity of 21.4 kOe, which corresponds to SH level, is achieved for HRE-free NdFeB magnet by doping with Ce85Al15 (CeAl) alloy and grain boundary diffusion (GBD) with Pr70Cu15Al15 (PrCuAl) alloy powders, where Ce/RE ratio is about 15% within the magnet. After GBD treatment with PrCuAl on Ce-containing NdFeB magnets, the formation of Pr-containing shell at 2:14:1 grain surface can increase the local magnetic anisotropy filed and therefore enhance the coercivity. Most of Cu and Al, and parts of Ce and Pr appear at grain boundary and triple junction, which can reduce the magnetization of grain boundary phase, strengthen the decoupling effect between grains and thus contribute to high coercivity. This study provides a cost-effective way to obtain high coercivity for HRE-free NdFeB sintered magnet via doping Ce85Al15 and then GBD with Pr70Cu15Al15. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. 110P Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC

Author

Cho, B.C., primary, Chiu, C-H., additional, Massarelli, E., additional, Chawla, S.P., additional, Buchschacher, G.L., additional, Goto, K., additional, Kim, S-W., additional, Overbeck, T.R., additional, Loong, H.H.F., additional, Chee, C.E., additional, Garrido, P., additional, Heinzmann, S., additional, Pitcher, B., additional, and John, T., additional

Published
2022
Full Text
View/download PDF

28. 111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours

Author

Lu, S., primary, Chiu, C-H., additional, Yu, Y., additional, Loong, H.H.F., additional, Lin, C.C., additional, Hu, X., additional, Dong, X., additional, Li, J., additional, Zhao, J., additional, Ye-Hui, S., additional, Zhang, Z., additional, Zhao, N., additional, Xia, J., additional, Wang, D., additional, and Fan, Y., additional

Published
2022
Full Text
View/download PDF

35. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN

Author

Zhou, Q., primary, Kim, H.R., additional, Soo, R., additional, Chang, G-C., additional, Chiu, C-H., additional, Hayashi, H., additional, Kim, S-W., additional, Teraoka, S., additional, Goto, Y., additional, Zhou, J., additional, Lee, V.H.F., additional, Han, B., additional, Ho, J.C.M., additional, Kim, D-W., additional, Lin, C-C., additional, Lu, S., additional, Polli, A., additional, Calella, A.M., additional, Mok, T.S.K., additional, and Wu, Y-L., additional

Published
2021
Full Text
View/download PDF

36. 1208P Final results of APOLLO study: Overall survival (OS) of aumolertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)

Author

Lu, S., primary, Wang, Q., additional, Zhang, G., additional, Dong, X., additional, Yang, C-T., additional, Song, Y., additional, Chang, G-C., additional, Lu, Y., additional, Pan, H., additional, Chiu, C-H., additional, Wang, Z., additional, Feng, J., additional, Zhou, J., additional, Xu, X., additional, Guo, R., additional, Chen, J., additional, Yang, H., additional, Chen, Y., additional, Yu, Z., additional, and Shiah, H-S., additional

Published
2021
Full Text
View/download PDF

39. 115P Survival data from EMPOWER-Lung 4: Phase II study of cemiplimab plus ipilimumab in the second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC)

Author

Shim, B.Y., primary, Lee, S., additional, Carpeño, J. de Castro, additional, Chiu, C-H., additional, Cobo, M., additional, Kim, H.R., additional, Ryu, J.S., additional, Tarruella, M. Majem, additional, Summers, Y., additional, Thomas, C.A., additional, Xu, Y., additional, Lowy, I., additional, and Rietschel, P., additional

Published
2021
Full Text
View/download PDF

42. Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline

Author

Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B., Doebele, R. C., Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B., and Doebele, R. C.

Published
2020

44. 299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC

Author

Tan, D.S.W., primary, Ahn, M-J., additional, Chiu, C-H., additional, Ohe, Y., additional, Loong, H.H.F., additional, Chee, C.E., additional, Kim, S-W., additional, Takeda, M., additional, Li, Y-C., additional, Cheng, A., additional, Hida, T., additional, Kim, D-W., additional, Nogami, N., additional, Su, W-C., additional, Tanaka, H., additional, Osborne, S., additional, Freund, R., additional, Chen, D., additional, and Seto, T., additional

Published
2020
Full Text
View/download PDF

49. 1269P EMPOWER-lung 4: Phase II, randomized, open-label high dose or standard dose cemiplimab alone/plus ipilimumab in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Author

Shim, B.Y., primary, Lee, S., additional, de Castro Carpeño, J., additional, Chiu, C-H., additional, Cobo, M., additional, Kim, H.R., additional, Ryu, J.S., additional, Tarruella, M.M., additional, Summers, Y., additional, Thomas, C.A., additional, Xu, Y., additional, Lowy, I., additional, and Rietschel, P., additional

Published
2020
Full Text
View/download PDF

50. 364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases

Author

John, T., primary, Chiu, C-H., additional, Cho, B.C., additional, Fakih, M., additional, Farago, A.F., additional, Demetri, G.D., additional, Goto, K., additional, Doebele, R.C., additional, Siena, S., additional, Drilon, A., additional, Patel, M.R., additional, Liu, S.V., additional, Ahn, M-J., additional, Bazhenova, L., additional, Overbeck, T.R., additional, Nieva, J., additional, Kim, S-W., additional, Veronese, L., additional, Day, B-M., additional, and De Braud, F., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results